UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: April 3, 2018

<u>Nevada</u>	<u>000-30262</u>	90-0273142	
(State or jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)	
500 Union Street, Suite 810 Seattle, Washington 98101 (206) 903-1351 (Address of Registrant's principal executive office and telephone number)			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:			
[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).			
Emerging growth company []			
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []			

Item 8.01 Other Events.

Issuance of Twelfth Patent on ChromaIDTM Technology

On April 5, 2018, Visualant, Incorporated (the "Company"), an emerging leader in next generation optical sensor technology, announced that it had received its twelfth patent relating to its ChromaIDTM technology. The invention relates to the use of the Company's ChromaIDTM technology for identifying and analyzing fluids or particles suspended in the fluid. It has a wide range of potential applications in substance identification, security screening, authentication, quality control and medical diagnostics and other industrial and consumer markets.

The patent, issued by the United States Patent and Trademark Office as US Patent No. 9,869,636 B2, is entitled "Device For Evaluation Of Fluids Using Electromagnetic Energy." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits -

Exhibit No.	Description
99.1	Press Release of Visualant, Inc. dated April 5, 2018 related to the twelfth patent award for the ChromaID TM technology.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Registrant: VISUALANT, INCORPORATED

By: <u>/s/ Ronald P. Erickson</u> Ronald P. Erickson, CEO

April 5, 2018



Visualant Granted Fluid Evaluation Patent

Disruptive Platform Technology Evaluates Fluids Using Electromagnetic Energy

Seattle, WA. – (April 5, 2018) Visualant, Incorporated (OTCQB: VSUL) – an emerging leader in next generation optical sensor technology – announced today that it has received its 12th U.S. patent. The invention relates to the use of the company's disruptive ChromaID™ technology for identifying and analyzing fluids or particles suspended in the fluid. It has a wide range of potential applications in substance identification, security screening, authentication, quality control and medical diagnostics and other industrial and consumer markets.

ChromaID is a platform technology that employs frequency-specific structured light to detect unique spectral patterns that occur naturally in virtually any type of substance or object. Unlike legacy optical sensor technology such as mass spectrometry, ChromaID sensors can provide highly accurate information at a significantly lower cost and in a small and flexible form factor. ChromaID sensors can be easily integrated into a variety of both hand-held and stationary systems used for inspection, analysis and authentication. ChromaID's affordability, unique functionality and compact size make it an attractive offering for both the consumer-facing and enterprise Internet of Things (IoT) ecosystems.

The Visualant ChromaID technology, as applied to the evaluation of fluids and particles suspended in fluids, will allow for a wide variety of real world applications involving identification, authentication and diagnostics, including water quality, medical diagnostics, and quality control and analysis. Examples may include real-time analysis of drinking water, authentication of the fluid in a hospital IV drip, detection of the presence of water in aviation jet fuel among so many other applications.

Visualant Founder and CEO Ron Erickson stated, "We believe this new patent will prove to be one of our most significant to date as it provides a foundation for the pursuit of a number of consumer, medical and industrial diagnostic and authentication applications. We continue to attract enthusiastic interest as we develop and pursue partnering opportunities in each of these large, global markets. We believe that the availability of strong patent protection helps to give our partners confidence that the products that they bring to market based on ChromaID technology can enjoy a significant and lasting competitive advantage."

The patent, issued by the United States Patent and Trademark Office as US Patent No. 9,869,636 B2, is entitled "Device For Evaluation Of Fluids Using Electromagnetic Energy." This newly issued patent continues the expansion of the Visualant intellectual property portfolio. The company continues to have a significant number of pending patents and aggressively works to expand the reach of its ChromaID and related electromagnetic technology.

About Visualant, Inc.

VisualantTM is a public company whose shares trade under the stock symbol "VSUL." The Visualant technology directs structured light and/or radio waves through or onto a substance or material, through a liquid or gas, or off a surface, to capture a unique molecular signature. The Company refers to these signatures as ChromaIDTM or Bio-RFIDTM. A ChromaID or Bio-RFID can be used to identify, detect, or diagnosis markers invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or fixed-mount form factors. The patented and patent pending, award-winning technology is disruptive, making it possible to effectively conduct analyses that could only previously be performed by invasive and often large and expensive lab-based tests. For more information on Visualant, visit the company's website at www.visualant.net.

Visualant Contact:

Ron Erickson Visualant, Inc. Ph. 206-903-1351 Email. ron@visualant.net